months of AICC infused prophylaxis (PX) with 6 months of on-demand (OD) therapy, separated by a 3-month washout period during which patients used on-demand therapy. HRQoL was summarized in two continuous variables: Physical Component Score (PCS-36) and Mental Component Score . The difference between two study periods for 6-month change from baseline in PCS-/MCS-36 are compared using Wilcoxon signed-rank test to measure the difference between two groups regardless of the sequence of medications. To investigate the effect of random sequence in the change of HRQoL, the difference between two study periods for 6-month change from baseline in PCS-/MCS-36 is compared by random sequence using Wilcoxon-Mann-Whitney U test with exact statement. RESULTS: Twenty-six patients completed both study periods. 17 of them were Ͼ14 years old and thus completed QoL questionnaires and are included in this analysis. The difference between PX and OD in 6-month change from baseline was 2.83 for PCS-36 (pϭ0.378) and 1.29 for MCS-36 (pϭ0.890), favored PX on both measures. Regardless of random sequence of medication, HRQoL showed a moderate improvement with PX. When comparing the difference of 6-month change by treatment sequence, patients who initiated with PX then switched to OD had a greater improvement compared to the opposite sequence (PX-ϾOD: 6.59, OD-ϾPX: 0.19 for PCS-36 (pϭ0.475); PX¡OD: 2.66, OD¡PX: 0.33 for MCS-36 (pϭ0.601)). CONCLUSIONS: A cross-over effect, albeit statistically non-significant, was observed when the difference of 6-month change was compared by treatment sequence. Patients who started with more favorable medication tended to show a greater improvement, whereas patients in opposite sequence showed a slight improvement.
months of AICC infused prophylaxis (PX) with 6 months of on-demand (OD) therapy, separated by a 3-month washout period during which patients used on-demand therapy. HRQoL was summarized in two continuous variables: Physical Component Score (PCS-36) and Mental Component Score . The difference between two study periods for 6-month change from baseline in PCS-/MCS-36 are compared using Wilcoxon signed-rank test to measure the difference between two groups regardless of the sequence of medications. To investigate the effect of random sequence in the change of HRQoL, the difference between two study periods for 6-month change from baseline in PCS-/MCS-36 is compared by random sequence using Wilcoxon-Mann-Whitney U test with exact statement. RESULTS: Twenty-six patients completed both study periods. 17 of them were Ͼ14 years old and thus completed QoL questionnaires and are included in this analysis. The difference between PX and OD in 6-month change from baseline was 2.83 for PCS-36 (pϭ0.378) and 1.29 for MCS-36 (pϭ0.890), favored PX on both measures. Regardless of random sequence of medication, HRQoL showed a moderate improvement with PX. When comparing the difference of 6-month change by treatment sequence, patients who initiated with PX then switched to OD had a greater improvement compared to the opposite sequence (PX-ϾOD: 6.59, OD-ϾPX: 0.19 for PCS-36 (pϭ0.475); PX¡OD: 2.66, OD¡PX: 0.33 for MCS-36 (pϭ0.601)). CONCLUSIONS: A cross-over effect, albeit statistically non-significant, was observed when the difference of 6-month change was compared by treatment sequence. Patients who started with more favorable medication tended to show a greater improvement, whereas patients in opposite sequence showed a slight improvement.
OBJECTIVES:A daily assessment of the speed of action and effectiveness of treatment of a combination of paracetamol and codeine in patients suffering from intense pain, which has progressed since less than 7 days. METHODS: A multicentre longitudinal observational prospective study carried out in metropolitan France using data collected by general practitioners who agreed to participate. RESULTS: A total of 574 patients treated by a paracetamol-codeine combination (600mg/50mg and 400mg/20mg) were included. The severity of pain measured at inclusion using a visual numeric scale was 7Ϯ1.28. The severity of pain measured after half a day of treatment was 5.61Ϯ1.87 and 5.28 Ϯ 1.86 at the end of the first 24 hours of treatment. A significant improvement in pain was observed from the first half-day (pϽ0.001). The severity of pain on the 2nd, 4th and 7th evenings was respectively 4.08Ϯ1.85; 2.76Ϯ1.76 and 1.79 Ϯ1.69 On D1, 69.7% declared treatment to be effective, 61.04% were satisfied with their treatment and 79.26% did not observe any side effects to the treatment. On D7, 96.15% (D3, 91.3% ) declared treatment to be effective, 87.10% were satisfied with their treatment and 88.96% did not observe any side effects to the treatment. 8 out of 10 patients did not complain about side effects related to the treatment. CONCLUSIONS: A reduction in pain within the first 12 hours showed the pertinence of treatment using a paracetamol-codeine combination. This pertinence was confirmed by two-thirds patients who declared the treatment to be effective from the 1st day, and 91% of them declared this on the 3rd day
OBJECTIVES:A daily assessment of the speed of action and effectiveness of treatment of a combination of paracetamol and codeine in patients suffering from intense pain, which has progressed since less than 7 days. METHODS: A multicentre longitudinal observational prospective study carried out in metropolitan France using data collected by general practitioners who agreed to participate. RESULTS: A total of 574 patients treated by a paracetamol-codeine combination (600mg/50mg and 400mg/20mg) were included. The severity of pain measured at inclusion using a visual numeric scale was 7Ϯ1.28. The severity of pain measured after half a day of treatment was 5.61Ϯ1.87 and 5.28 Ϯ 1.86 at the end of the first 24 hours of treatment. A significant improvement in pain was observed from the first half-day (pϽ0.001). The severity of pain on the 2nd, 4th and 7th evenings was respectively 4.08Ϯ1.85; 2.76Ϯ1.76 and 1.79 Ϯ1.69 On D1, 69.7% declared treatment to be effective, 61.04% were satisfied with their treatment and 79.26% did not observe any side effects to the treatment. On D7, 96.15% (D3, 91.3% ) declared treatment to be effective, 87.10% were satisfied with their treatment and 88.96% did not observe any side effects to the treatment. 8 out of 10 patients did not complain about side effects related to the treatment. CONCLUSIONS: A reduction in pain within the first 12 hours showed the pertinence of treatment using a paracetamol-codeine combination. This pertinence was confirmed by two-thirds patients who declared the treatment to be effective from the 1st day, and 91% of them declared this on the 3rd day
agnosis, duration of disease, clinical and laboratory symptoms, procedures of dialysis and antianemic therapy). Health-related quality of life was assessed with self-administrated validated version of Russian version of Euroqol-5D questionnaire. Inclusion criteria were age older than 18 years, terminal stage of chronic renal failure and treatment with dialysis more then 4 months. RESULTS: 1395 completed questionnaires were received by September, 2010. Mean age was 42 years. 45% patients reported chronic glomerulonephritis as a main reason of chronic renal failure, 22% -chronic pyelonephritis, 10% -diabetes, 8% -polycystic kidney disease, other diseases -1,5%. Average level of hemoglobin was 107Ϯ16.2 g/l. 80% of patients reported that they got 12-14 procedures of dialysis during last month. The average length of one procedure was 4-5 hours just for 17% of patients, in other cases (80%) length of dialysis was shorter. Analysis of antianemic therapy has shown that 85% got erytropoetins and 70% -iron supplements. More than half of patients reported problems within each of EQ-5D dimensions of health. Thus 42.5% of patients reported problems with mobility, 20% -difficulties with self-care; 58.7% -difficulties with usual activities; 67% -reported about pain or discomfort; 47% -reported about an anxiety or depression. The average value of quality of life evaluated with visual-analog scale (VAS) was 0.59 (SD 0.17), median -0.6. CONCLUSIONS: Analyses of quality of life have demonstrated high rate of problem with usual activity and pain and discomfort and low rate of problem with selfservice. OBJECTIVES: To assess health status, treatment patterns and quality of life in patients with hereditary coagulopathies in Ukraine. METHODS: Postal health survey. Questionnaires were distributed in May -August 2009. Health-related quality of life was assessed with self-administrated validated version of Russian version of Euroqol-5D questionnaire. Comparison was made with data about health-related quality of life of Russian patients (P.Vorobeyv et. al., 2008, data of 1003 patients was used in analyses). Analysis of experimental data was performed with 2 criteria. RESULTS: 154 completed questionnaires were received by September, 2009.Health-related quality of life was assessed for patients older than 11 years (n ϭ 142). More than half of patients reported problems within each of EQ-5D dimensions of health. Thus 88.8% of patients reported of problems (moderate and severe) with mobility (63.9% of Russian patients, pϽ0.05), 57.7% of patients inform of difficulties with self-care (35.5% of Russian patients, pϽ0.05); 81% of patients had difficulties with usual activity (61.9% of Russian patients, pϽ0.05); 90.9% of patients reported of presence of pain/discomfort (78.9% of Russian patients, pϽ0.05); 60.5% of patients had an anxiety or depression (54.2% of Russian patients, pϾ0.05). The average value of quality of life according to visual-analog scale was 0.44 (SD 0.22). CONCLUSIONS:The study of quality of life in patients with hereditary coagu...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.